Literature DB >> 837481

The effect of "ischemic" blood on transmembrane potentials of normal porcine ventricular myocardium.

E Downar, M J Janse, D Durrer.   

Abstract

"Ischemic" blood was obtained in pigs from a local coronary vein on release of coronary artery occlusion. The effects of this blood on transmembrane potentials of muscle strips taken from the same heart were compared with control blood. Whereas action potentials remained stable in control blood, ischemic blood collected after more than 15 minutes of coronary occlusion produced shortening of action potential duration, reduction of resting potential, upstroke velocity and amplitude, then postrepolarization refractoriness and finally unresponsiveness. Ischemic blood collected after shorter periods of coronary occlusion produced only mild effects (shortening of action potential and postrepolarization refractoriness). These effects of ischemic blood could not be attributed to increased potassium concentration even in combination with acidosis, hypoxia and hypoglycemia. It appears that during ischemia unidentified factors are released which have potent depressant effects on the excitability of even normal myocardium.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837481     DOI: 10.1161/01.cir.55.3.455

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

1.  Effects of lysophosphatidylcholine on electrophysiological properties and excitation-contraction coupling in isolated guinea pig ventricular myocytes.

Authors:  E Liu; J I Goldhaber; J N Weiss
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

2.  Effects of lysophosphatidylcholine on resting potassium conductance of isolated guinea pig ventricular cells.

Authors:  T Kiyosue; M Arita
Journal:  Pflugers Arch       Date:  1986-03       Impact factor: 3.657

3.  Electrical changes produced by injury to the rat myocardium in vitro and the protective effects of certain antiarrhythmic drugs.

Authors:  B J Northover
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

4.  Electrophysiological effects of diltiazem, nifedipine and Ni2+ on the subepicardial muscle cells of canine heart under the condition of combined hypoxia, hyperkalemia and acidosis.

Authors:  S Kimura; H Nakaya; M Kanno
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-11       Impact factor: 3.000

5.  Mechanoelectrical feedback: independent role of preload and contractility in modulation of canine ventricular excitability.

Authors:  B B Lerman; D Burkhoff; D T Yue; M R Franz; K Sagawa
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

6.  Transmembrane potential changes and ventricular fibrillation during repetitive myocardial ischaemia in the dog.

Authors:  D C Russell; J H Smith; M F Oliver
Journal:  Br Heart J       Date:  1979-07

7.  Acute regional left atrial ischemia causes acceleration of atrial drivers during atrial fibrillation.

Authors:  Masatoshi Yamazaki; Uma Mahesh R Avula; Krishna Bandaru; Auras Atreya; Venkata Subbarao C Boppana; Haruo Honjo; Itsuo Kodama; Kaichiro Kamiya; Jérôme Kalifa
Journal:  Heart Rhythm       Date:  2013-02-21       Impact factor: 6.343

8.  Nonhomogeneous electrophysiological changes and the bimodal distribution of early ventricular arrhythmias during acute coronary artery occlusion.

Authors:  T Horacek; M Neumann; S von Mutius; M Budden; W Meesmann
Journal:  Basic Res Cardiol       Date:  1984 Nov-Dec       Impact factor: 17.165

9.  Role of some components of ischemia in the genesis of spontaneous ventricular arrhythmias.

Authors:  J Senges; H Seller; J Brachmann; W Braun; E Mayer; I Rizos; W Kübler
Journal:  Basic Res Cardiol       Date:  1984 Jan-Feb       Impact factor: 17.165

10.  Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium.

Authors:  B E Sobel; P B Corr; A K Robison; R A Goldstein; F X Witkowski; M S Klein
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.